2022 ACA New Orleans Program Book_152nd Congress of Correction

Moderator: Dr. Brandon L. Warren , Director of Reentry Services, College Huntsville, Center Huntsville, Texas Speakers: Matthew McGinnis , Reentry Specialist, Lee College Huntsville Center, Huntsville, Texas; Dr. Brandon L. Warren , Director of Reentry Services, College Huntsville, Center Huntsville, Texas; Tracy P. Williams , Reentry Specialist, Lee College Huntsville Center, Huntsville, Texas C-4E The Evolution of HIV Treatment and 340b Drug Pricing Programs (CE-RN, CME) Room 255 Track: Physician Corrections This presentation will provide an overview of the evolution of HIV/AIDS treatment from its discovery as a new disease in 1981 until today. In addition, we will provide an overview of how the 340b Drug Pricing Program evolved over time, and how it is currently used under different models in Virginia and Florida to provide high quality, cost-effective treatment to inmate patients. Learning Objectives: 1.Participants will be able to define the evolution of HIV/AIDS treatment from 1981 to today. 2.Participants will be able to discuss how two states are using different 340b Drug

Pricing Program models to provide high quality, cost-effective HIV/AIDS treatment to inmate patients. 3.Participants will be able to identify HIV/ AIDS treatment in correctional settings. Moderator: Thomas Reimers , Health Services Director, Florida Department of Corrections, Tallahassee, Florida Speakers: Trey Fuller , PharmD, Assistant Director of Health Services, Virginia Department of Corrections, Richmond, Virginia; Danny Martinez , M.D., MPH, Chief of Medical Services, Florida Department of Corrections, Tallahassee, Florida; Thomas Reimers , Health Services Director, Florida Department of Corrections, Tallahassee, Florida C-4F Implementation of Extended-Release Buprenorphine for the Treatment of Opioid Use Disorder in a Rural Maine Jail (CE-RN, CME) Room 256 Track: Multi-Disciplinary Service Team Extended-release Buprenorphine reduces staffing expenses and diversion risk and enables individuals to continue receiving treatment for 28 days post-release. The medication is associated with fewer jail medical visits, a higher rate of treatment retention, a lower rate of recidivism and

Workshops Saturday, Aug. 6 t 3:30–5 p.m.

132 — ACA 152 nd Congress of Correction